½ÃÀ庸°í¼­
»óǰÄÚµå
1419137

¼¼°è ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå : Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® - À¯·¡º°, Á¦Ç°º°, ¿ëµµº°

Monocyte Activation Tests Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Source (PMBC and Cell Line), Products (MAT Kits and Reagents), and Application

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 6,517¸¸ 4,000´Þ·¯¿¡ À̸£·¶°í, ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 17.5%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 2¾ï 3,671¸¸ 4,000´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå ºÐ¼®Àº Á¦¾à, »ý¸í °øÇÐ, ÀÇ·á±â±â µîÀÇ ÃÖÁ¾ »ç¿ëÀÚ »ê¾÷¿¡¼­ ȯÀÚÀÇ ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁö°í,º¸´Ù ¾ÈÀüÇÑ ÆÄÀÌ·ÎÁ¨ ½ÃÇè¹ý¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõ µî ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ Á¶»ç°¡ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè¹ýÀÇ ±â¼ú °³Ã´Àº ¿¹Ãø ±â°£ µ¿¾È ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±â¿øÀ» ¹ÙÅÁÀ¸·Î, ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀº PMBC¿Í ¼¼Æ÷ÁÖ·Î À̺е˴ϴÙ. PMBC ºÎ¹®Àº 2022³â¿¡ Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È¿¡µµ À¯»çÇÑ °æÇâÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦Ç°º°·Î ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀº MAT ŰƮ ¹× ½Ã¾àÀ¸·Î À̺е˴ϴÙ. MAT ŰƮ ºÐ¾ß´Â 2022³â¿¡ Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ºñ½ÁÇÑ °æÇâÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÑÆí, ½Ã¾à ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ´õ ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿ëµµ¿¡ µû¶ó ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀº ÀǾàǰ °³¹ß, ¹é½Å °³¹ß, ÀÇ·á±â±â, ±âŸ(¿¬±¸ µî)·Î ±¸ºÐµË´Ï´Ù. ÀǾàǰ °³¹ß ºÎ¹®Àº 2022³â¿¡ ÃÖ´ëÀÇ Á¡À¯À²À» ȹµæÇϰí 2022-2030³â±îÁö °°Àº µ¿ÇâÀÌ ¿¹»óµË´Ï´Ù.

´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇèÀº ¿£µµÅå½Å°ú ºñ-¿£µµÅå½Å ÆÄÀ̷ΰÕÀÇ »ó½ÂÀÛ¿ë¿¡ ÀÇÇÑ »çÀÌÅäÄ«ÀÎ ¹æÃâÀÇ Áõ°­À» °ËÃâÇÕ´Ï´Ù. ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè(MAT)Àº ºñ°æ±¸ ¾à¹°, »ý¹°ÇÐÀû Á¦Á¦, ÀÇ·á±â±â¿¡ ´ëÇÑ ¸ðµç ºÐ·ùÀÇ ÆÄÀÌ·ÎÁ¨À» °Ë»çÇϱâ À§ÇØ °í¾ÈµÈ ½ÃÇè°ü³» ºÐ¼®ÀÔ´Ï´Ù. Áö³­ 5³â°£ ·¡ºø ÆÄÀÌ·ÎÁ¨ Å×½ºÆ®¸¦ ¸±¸®Áî ºÐ¼®À¸·Î »ç¿ëÇÑ ¹é½ÅÀÌ ´ÜÇÙ±¸ Ȱ¼ºÈ­ Å×½ºÆ®(MAT)¸¦ óÀ½À¸·Î äÅÃÇß½À´Ï´Ù. °Ô´Ù°¡, MAT¿Í´Â ´Þ¸®, ¼¼±Õ¼º ¿£µµÅå½Å °Ë»ç´Â º»ÁúÀûÀ¸·Î ÆÄÀÌ·ÎÁ¦´Ð Á¦Ç°À̳ª ¼ö»êÈ­¾Ë·ç¹Ì´½°ú °°Àº ¹é½Å¿¡ ÀÚÁÖ Æ÷ÇԵǴ ÷°¡¹°À» Æ÷ÇÔÇÏ´Â Á¦Ç°¿¡´Â ÀûÇÕÇÏÁö ¾ÊÀº °æ¿ì°¡ ¸¹À¸¸ç, À̵éÀº ºÐ¼®À» ¹æÇØÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. MAT°¡ ¹é½Å °Ë»ç¿¡ ä¿ëµÈ ¿¹·Î´Â ¼ö¸·¿°±Õ ¹é½Å, °í¸é¿ªÇ÷û, Ȳ¿­º´ ¹é½Å, ÀÌÁú±Õ ¹é½Å, ±¤°ßº´ ¹é½Å, BÇü °£¿° ¹é½Å, Áøµå±â ¸Å°³ ³ú¿° ¹ÙÀÌ·¯½º ¹é½Å µîÀÌ ÀÖ½À´Ï´Ù.

À¯·¡º° ÀλçÀÌÆ®

´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀº ±â¿ø¿¡ ±âÃÊÇÏ¿© PMBC¿Í ¼¼Æ÷ÁÖ·Î À̺е˴ϴÙ. PMBC ºÎ¹®Àº 2022³â¿¡ Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È¿¡µµ À¯»çÇÑ °æÇâÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÎ¹®Àº 2022³âºÎÅÍ 2030³â±îÁö ´õ ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇöÀç Mono-Mac-6(MM6) ¼¼Æ÷ÁÖ¿Í ¸»ÃÊÇ÷´ÜÇÙ¼¼Æ÷(PBMC)ÀÇ 2À¯ÇüÀÇ ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè¿ë ¼¼Æ÷¼Ò½º°¡ »ó¾÷È­µÇ°í ÀÖ½À´Ï´Ù. MM6Àº ÇÑ ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´ ȯÀÚÀÇ Ç÷¾×¿¡¼­ ÆÄ»ýµË´Ï´Ù. ±× °á°ú, ´ÜÇÙ±¸´Â º´¿ø¼º ¿À¿°¹°ÁúÀ» ÀϰüµÇ°Ô °ËÃâÇÏ°í °Ç°­ÇÑ Àΰ£¿¡ ÀÇÇÑ »çÀÌÅäÄ«ÀÎÀÇ ¹æÃâÀ» °³½ÃÇϴµ¥ ÇÊ¿äÇÑ ¾ÈÁ¤ÇÑ ¹ßÇöÀ» ¹Ý¿µÇÏ´Â TLRÀ» °®Áö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­, ÀÌ ¼¼Æ÷¿øÀ» ÀÌ¿ëÇÑ MAT °á°úÀÇ ÀçÇö¼ºÀº ³·½À´Ï´Ù. Ph.Eur.(2.6.30)¿¡¼­µµ MM6 ±â¹Ý MAT ŰƮ´Â ºñ-¿£µµÅå½Å¼º ÆÄÀÌ·ÎÁ¨ÀÇ °ËÃâ¿¡ À־ "Á¦ÇÑÀû"À̶ó°í ±â¼úµÇ¾î ÀÖ½À´Ï´Ù.

ÇÑÆí, PBMC ±â¹Ý MAT ŰƮ´Â ½ºÅ©¸®´×µÈ °Ç°­ÇÑ ±âÁõÀÚ Ç® Ç÷¾×¿¡¼­ PBMC¸¦ °ø±ÞÇÕ´Ï´Ù. ÀÌ´Â ½ºÆÄÀÌÅ©µÈ Á¦Ç° »ùÇðú ÇÔ²² ¹è¾çÇÑ °æ¿ì ´ÜÇÙ±¸ÀÇ È°¼ºÈ­°¡ °Ç°­ÇÑ Àΰ£ ¼ºÀåÀ» µµ¿ï ¼ö ÀÖÀ½À» ÀǹÌÇÕ´Ï´Ù. ±× °á°ú, ÀÌ ¼¼Æ÷¿ø¿¡ ±âÃÊÇÑ MAT ŰƮÀÇ °á°ú´Â ÀϰüµÇ°Ô ÀçÇö¼ºÀÌ ÀÖ´Â °ÍÀ¸·Î ¹àÇôÁ³½À´Ï´Ù. Ph.Eur.(2.6.30)¿¡¼­ ÀÌ ¼¼Æ÷¿øÀº endotoxin°ú non-endotoxin pylogenÀ» ¸ðµÎ °ËÃâÇÏ´Â ´É·ÂÀÌ ³ô´Ù°í ÇÕ´Ï´Ù.

ÇöÀç ´Ù¸¥ PBMC ±â¹Ý ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè º¥´õ 3°³»ç°¡ ½ÃÆÇ ÁßÀÔ´Ï´Ù. °¢ LoD´Â 0.125 EU/ml, 0.02 EU/ml, 0.016 EU/mlÀÔ´Ï´Ù. CTL-MAT ºÐ¼®ÀÇ LoD´Â 0.004 EU/ml·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, ¼¼°è¿¡¼­ ÀÌ¿ë °¡´ÉÇÑ ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè Áß¿¡¼­ °¡Àå °í°¨µµÀÔ´Ï´Ù.

Á¦Ç° ±â¹Ýº° ÀλçÀÌÆ®

Á¦Ç°¿¡ µû¶ó ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀº MAT ŰƮ ¹× ½Ã¾àÀ¸·Î À̺е˴ϴÙ. MAT ŰƮ ºÐ¾ß´Â 2022³â¿¡ Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ºñ½ÁÇÑ °æÇâÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÑÆí, ½Ã¾à ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ´õ ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº° ºÐ¼®

´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀº Áö¿ªº°·Î ±¸ºÐµÈ´Ù: ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áß³²¹Ì, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â 2022³â ÃÖ´ë ½ÃÀå Á¡À¯À²À» ȹµæÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ºñ½ÁÇÑ °æÇâÀÌ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, À̾î À¯·´ÀÌ À̾îÁý´Ï´Ù. ¹Ì±¹ ¾àÀü(USP)°ú ij³ª´Ù Á¤ºÎ¿Í °°Àº Á¶Á÷¿¡ ÀÇÇÑ ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇèÀÇ ±ÔÁ¦ °üÇàÀº ÀÌ Áö¿ª¿¡¼­ ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå ÀüüÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚÀÇ ¾ÈÀü¼º¿¡ ´ëÇÑ °ü½É°ú ÇコÄÉ¾î ¼º°ú Çâ»ó¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ºÏ¹Ì ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

Merck KGaA, Darmstadt, Germany and/or its affiliates, Charles River Laboratories International, Inc, Thermo Fisher Scientific, Sanquin, Lonza GroupÀº ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ Áß ÇϳªÀÔ´Ï´Ù.

2023³â 10¿ù, Lonza´Â Åä³¢¸¦ »ç¿ëÇÏÁö ¾Ê´Â ÆÄÀÌ·ÎÁ¨ °Ë»ç¸¦ °£¼ÒÈ­ÇÏ°í ¿ëÀÌÇÏ°Ô Çϱâ À§ÇØ µÎ °³ÀÇ ½Å¼ÓÇÑ ´ÜÇÙ±¸ Ȱ¼ºÈ­ ½ÃÇè(MAT) ½Ã½ºÅÛ, ÆÄÀ̷μ¿ MAT ½Å¼ÓÇÑ ½Ã½ºÅÛ ¹× ÆÄÀ̷μ¿ MAT Àΰ£ Ç÷û(HS) ½Å¼ÓÇÑ ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ·ÐÀÚ°¡ ±âÁ¸¿¡ Á¦°øÇØ ¿Â MAT ½Ã½ºÅÛ Å°Æ®¸¦ ´ëüÇÏ¸ç »õ·Î Ãâ½ÃµÇ´Â Á¦Ç°Àº ÀÛ¾÷ ½Ã°£À» ÃÖ¼ÒÈ­ÇÏ°í °á°ú¸¦ ¾òÀ» ¶§±îÁöÀÇ ½Ã°£À» 2ÀÏ¿¡¼­ 2½Ã°£À¸·Î ´ÜÃàÇÏ´Â »õ·Î¿î PeliKine Àΰ£ IL-6 ºü¸¥ ELISA ŰƮ°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÀÌ »õ·Î¿î °Ë»ç´Â Á¦¾à ¹× »ý¸í °øÇÐ Á¦Á¶¾÷ü¿¡°Ô Á¦Ç°ÀÇ ¾ÈÀü¼º Å×½ºÆ®¸¦À§ÇÑ ´õ °£´ÜÇÑ MAT °Ë»ç ¿É¼ÇÀ» Á¦°øÇÏ°í µ¿½Ã¿¡ µ¿¹°¿¡ ´ëÇÑ ÀÇÁ¸¼ºÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀåÀ» Á¶»çÇÒ ¶§ ¾ð±ÞÇÑ ´Ù¸¥ Ȱµ¿À¸·Î´Â The Therapeutic Goods Administration, The Humane Society of the United States, National Institutes of Health µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå »óȲ

  • PEST ºÐ¼®
  • »ýÅÂ°è ºÐ¼®
    • ¹ë·ùüÀÎÀÇ º¥´õ À϶÷

Á¦5Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ±âȸ
  • ÇâÈÄÀÇ µ¿Çâ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®

Á¦6Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

  • ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ¼¼°è ½ÃÀå °³¿ä
  • ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ¼¼°è ½ÃÀå ¿¹Ãø(-2030³â)

Á¦7Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå - ¼öÀÍ ºÐ¼® : À¯·¡º°(2020³â-2030³â)

  • °³¿ä
  • PMBC
  • ¼¼Æ÷ ¶óÀÎ

Á¦8Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå - ¼öÀÍ ºÐ¼® : Á¦Ç°º°(2020³â-2030³â)

  • °³¿ä
  • MAT ŰƮ
  • ½Ã¾à

Á¦9Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå - ¼öÀÍ ºÐ¼® : ¿ëµµº°(2020³â-2030³â)

  • °³¿ä
  • ÀǾàǰ °³¹ß
  • ¹é½Å °³¹ß
  • ÀÇ·á±â±â
  • ±âŸ(Á¶»ç µî)

Á¦10Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå - ¼öÀÍ ºÐ¼® : Áö¿ªº°(2020³â-2030³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¿µ±¹
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áß³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ Áß³²¹Ì

Á¦11Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ

Á¦12Àå »ê¾÷ Á¤¼¼

  • ÇÕº´°ú Àμö
  • °è¾à, Á¦ÈÞ, ÇÕÀÛ »ç¾÷
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë ¹× ±âŸ Àü·«Àû Àü°³

Á¦13Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷ÀÇ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ Æ÷Áö¼Å´×°ú ÁýÁßµµ

Á¦14Àå ´Ü±¸ Ȱ¼ºÈ­ ½ÃÇè ½ÃÀå - ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Merck KGaA, Darmstadt,Germany and/or its Affiliates
  • Charles River Laboratories International, Inc.
  • Thermo Fisher Scientific
  • Sanquin
  • Lonza Group
  • MAT Biotech
  • Cellmade Laboratories
  • Labor LS SE & Co. KG
  • BD Biosciences
  • Beckman Coulter

Á¦15Àå ºÎ·Ï

BJH 24.02.16

The monocyte activation tests market size was valued at US$ 65.174 million in 2022 and is expected to reach US$ 236.714 million by 2030; it is estimated to register a CAGR of 17.5% from 2022 to 2030.

The monocyte activation tests market analysis includes the study of market drivers such as a rise in patient safety concerns and a surge in demand for safer pyrogen testing methods in end-user industries such as pharmaceutical, biotech, and medical devices. Further, technological developments in monocyte activation test methods are anticipated to propel the monocyte activation tests market growth during the forecast period.

Based on the source, the monocyte activation tests market is bifurcated into PMBC and cell lines. The PMBC segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. Based on products, the monocyte activation tests market is bifurcated into MAT kits and reagents. The MAT kits segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. On the other hand, the reagents segment is anticipated to record a higher CAGR during the forecasted period. Based on application, the monocyte activation tests market is segmented into drug development, vaccine development, medical devices, and others (research, etc.). The drug development segment captured the largest share in 2022 and is expected to witness the same trend from 2022 to 2030.

The monocyte activation test detects potentiated cytokine release from the synergistic effect of endotoxin and non-endotoxin pyrogens. The monocyte activation test (MAT) is an in-vitro assay designed to test parenteral drugs, biologics, and medical devices for all classifications of pyrogens. Over the last five years, vaccines that previously used the Rabbit Pyrogen Test as their release assay has been among the initial adopters of the monocyte activation test (MAT). Moreover, unlike MAT, bacterial endotoxin tests are often unsuitable for intrinsically pyrogenic products or those that include additives commonly included in vaccines, such as aluminum hydroxide, which tend to interfere with the assay. A few instances of MAT's uptake in testing vaccines included Neisseria meningitidis vaccine, Hyperimmune Sera, Meningococcal vaccines, Yellow fever vaccine, Shigella sonnei vaccine, Rabies vaccine, Hepatitis B Vaccine, and Tick-borne encephalitis virus vaccine.

Source-based Insights

Based on the source, the monocyte activation tests market is bifurcated into PMBC and cell lines. The PMBC segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. The same segment is expected to witness a higher CAGR from 2022 to 2030. Currently, two commercialized monocyte activation test cell sources are available globally-the Mono-Mac-6 (MM6) cell line and Peripheral Blood Mononuclear Cells (PBMC). The MM6 derives from the blood of a single acute monocytic leukemia patient; as a result, the monocytes sometimes do not have TLRs that reflect the stable expression required to consistently detect pyrogenic contaminants and initiate the release of cytokines by a healthy human. Hence, the reproducibility of MAT results is low using this cell source. The Ph. Eur. (2.6.30) also describes MM6-based MAT kits as "limited" in detecting non-endotoxin pyrogens.

On the other hand, PBMC-based MAT kits source their PBMC from the pooled blood of screened, healthy donors-which means that when incubated with a spiked product sample, the monocyte activation can assist the growth of a healthy human being. As a result, results for MAT kits based on this cell source have been consistently found to be reproducible. The Ph. Eur. (2.6.30) counts this cell source as proficient in detecting both endotoxins and non-endotoxin pyrogens.

Currently, three other commercialized PBMC-based monocyte activation test vendors are on the market. Each has a LoD of 0.125 EU/ml, 0.02 EU/ml, and 0.016 EU/ml. The CTL-MAT assay has a market-leading LoD of 0.004 EU/ml, making it the most sensitive monocyte activation test available worldwide.

Products-based Insights

Based on products, the monocyte activation tests market is bifurcated into MAT kits and reagents. The MAT kits segment held a larger share in 2022 and is expected to continue a similar trend during the forecast period. On the other hand, the reagents segment is expected to register a higher CAGR during the forecasted period.

Regional Analysis

The monocyte activation tests market is segmented based on region: North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. North America captured the largest market share in 2022 and is expected to continue a similar trend during the forecast period, followed by Europe. Regulatory practices of monocyte activation tests by organizations such as United States Pharmacopeia (USP) and the Government of Canada have further fueled the overall growth of the monocyte activation tests market in the region. Also, increasing focus on patient safety concerns and improved healthcare outcomes is one factor aiding North America's market growth.

Merck KGaA, Darmstadt, Germany and/or its affiliates; Charles River Laboratories International, Inc.; Thermo Fisher Scientific; Sanquin; and Lonza Group are among the leading companies operating in the monocyte activation tests market.

In October 2023, Lonza launched two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and ease rabbit-free pyrogen testing. The systems will replace Lonza's traditional MAT system kit offerings, and the newly launched products contain the new PeliKine Human IL-6 Rapid ELISA Kit that minimizes hands-on time and reduces time-to-results from two days to two hours. The new tests give pharmaceutical and biotechnology manufacturers easier MAT testing options for product safety testing while helping to reduce the reliance on animals.

Some sources referred while conducting the monocyte activation tests market are Therapeutic Goods Administration, The Humane Society of the United States, and the National Institutes of Health, among others.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Monocyte Activation Tests Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Monocyte Activation Tests Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Monocyte Activation Tests Market - Global Market Analysis

  • 6.1 Monocyte Activation Tests - Global Market Overview
  • 6.2 Monocyte Activation Tests - Global Market and Forecast to 2030

7. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Source, 2020-2030

  • 7.1 Overview
  • 7.2 PMBC
  • 7.3 Cell Line

8. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Products, 2020-2030

  • 8.1 Overview
  • 8.2 MAT Kits
  • 8.3 Reagents

9. Monocyte Activation Tests Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 9.1 Overview
  • 9.2 Drug Development
  • 9.3 Vaccine Development
  • 9.4 Medical Devices
  • 9.5 Others (Research etc.)

10. Monocyte Activation Tests Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Monocyte Activation Tests Market Overview
    • 10.1.2 North America Monocyte Activation Tests Market Revenue and Forecasts to 2030
    • 10.1.3 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Source
    • 10.1.4 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Products
    • 10.1.5 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Application
    • 10.1.6 North America Monocyte Activation Tests Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Monocyte Activation Tests Market
        • 10.1.6.1.1 United States Monocyte Activation Tests Market, by Source
        • 10.1.6.1.2 United States Monocyte Activation Tests Market, by Products
        • 10.1.6.1.3 United States Monocyte Activation Tests Market, by Application
      • 10.1.6.2 Canada Monocyte Activation Tests Market
        • 10.1.6.2.1 Canada Monocyte Activation Tests Market, by Source
        • 10.1.6.2.2 Canada Monocyte Activation Tests Market, by Products
        • 10.1.6.2.3 Canada Monocyte Activation Tests Market, by Application
      • 10.1.6.3 Mexico Monocyte Activation Tests Market
        • 10.1.6.3.1 Mexico Monocyte Activation Tests Market, by Source
        • 10.1.6.3.2 Mexico Monocyte Activation Tests Market, by Products
        • 10.1.6.3.3 Mexico Monocyte Activation Tests Market, by Application

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Pre and Post Covid-19 Impact

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Monocyte Activation Tests Market - Key Company Profiles

  • 14.1 Merck KGaA, Darmstadt,Germany and/or its Affiliates
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 14.2 Charles River Laboratories International, Inc.
  • 14.3 Thermo Fisher Scientific
  • 14.4 Sanquin
  • 14.5 Lonza Group
  • 14.6 MAT Biotech
  • 14.7 Cellmade Laboratories
  • 14.8 Labor LS SE & Co. KG
  • 14.9 BD Biosciences
  • 14.10 Beckman Coulter

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦